MiNK Therapeutics (INKT) Competitors $0.70 +0.02 (+2.92%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends INKT vs. ELEV, CYAD, DTIL, ATRA, CELU, CABA, VXRT, RANI, DERM, and IPSCShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Elevation Oncology (ELEV), Celyad Oncology (CYAD), Precision BioSciences (DTIL), Atara Biotherapeutics (ATRA), Celularity (CELU), Cabaletta Bio (CABA), Vaxart (VXRT), Rani Therapeutics (RANI), Journey Medical (DERM), and Century Therapeutics (IPSC). These companies are all part of the "medical" sector. MiNK Therapeutics vs. Elevation Oncology Celyad Oncology Precision BioSciences Atara Biotherapeutics Celularity Cabaletta Bio Vaxart Rani Therapeutics Journey Medical Century Therapeutics MiNK Therapeutics (NASDAQ:INKT) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, community ranking, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings. Which has better earnings and valuation, INKT or ELEV? MiNK Therapeutics is trading at a lower price-to-earnings ratio than Elevation Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$22.46M-$0.39-1.81Elevation OncologyN/AN/A-$45.70M-$0.82-0.71 Do analysts recommend INKT or ELEV? MiNK Therapeutics currently has a consensus price target of $6.50, indicating a potential upside of 822.12%. Elevation Oncology has a consensus price target of $7.80, indicating a potential upside of 1,242.28%. Given Elevation Oncology's higher probable upside, analysts plainly believe Elevation Oncology is more favorable than MiNK Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Elevation Oncology 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer INKT or ELEV? In the previous week, MiNK Therapeutics had 16 more articles in the media than Elevation Oncology. MarketBeat recorded 16 mentions for MiNK Therapeutics and 0 mentions for Elevation Oncology. MiNK Therapeutics' average media sentiment score of 0.22 beat Elevation Oncology's score of -0.25 indicating that MiNK Therapeutics is being referred to more favorably in the media. Company Overall Sentiment MiNK Therapeutics Neutral Elevation Oncology Neutral Which has more volatility and risk, INKT or ELEV? MiNK Therapeutics has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Does the MarketBeat Community favor INKT or ELEV? Elevation Oncology received 15 more outperform votes than MiNK Therapeutics when rated by MarketBeat users. However, 75.00% of users gave MiNK Therapeutics an outperform vote while only 73.17% of users gave Elevation Oncology an outperform vote. CompanyUnderperformOutperformMiNK TherapeuticsOutperform Votes1575.00% Underperform Votes525.00% Elevation OncologyOutperform Votes3073.17% Underperform Votes1126.83% Is INKT or ELEV more profitable? MiNK Therapeutics' return on equity of 0.00% beat Elevation Oncology's return on equity.Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -189.14% Elevation Oncology N/A -59.73%-40.05% Do institutionals & insiders have more ownership in INKT or ELEV? 2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are owned by institutional investors. 19.7% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 8.1% of Elevation Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryMiNK Therapeutics and Elevation Oncology tied by winning 7 of the 14 factors compared between the two stocks. Ad Behind the Markets📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Take these 4 steps to protect your retirement here >>> Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.88M$2.94B$5.01B$8.81BDividend YieldN/A1.89%5.21%4.07%P/E Ratio-1.8143.12126.5217.52Price / SalesN/A359.351,203.9085.12Price / CashN/A160.0933.3732.51Price / Book-1.363.734.684.68Net Income-$22.46M-$41.63M$118.36M$225.62M7 Day Performance-11.27%-7.94%-2.46%-2.04%1 Month Performance3.21%-7.19%-4.06%0.03%1 Year Performance-34.12%23.01%29.55%24.47% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics2.8641 of 5 stars$0.70+2.9%$6.50+822.1%-34.1%$27.88MN/A-1.8130Analyst RevisionELEVElevation Oncology2.0048 of 5 stars$0.58flat$7.80+1,242.3%+24.0%$34.35MN/A-0.7140CYADCelyad OncologyN/A$0.60flatN/A+0.0%$15.91M$110,000.000.0095High Trading VolumeDTILPrecision BioSciences4.0289 of 5 stars$7.18+0.3%$39.50+450.1%-46.6%$55.07M$48.73M119.35200Gap UpATRAAtara Biotherapeutics3.8122 of 5 stars$10.68-2.8%$16.67+56.1%-23.4%$61.52M$8.57M-0.41165CELUCelularity0.5401 of 5 stars$2.94+0.7%N/A+42.7%$64.64M$42.69M0.00220News CoverageCABACabaletta Bio2.0246 of 5 stars$2.26-11.0%$27.30+1,108.0%-87.4%$110.47MN/A-1.0550Analyst ForecastHigh Trading VolumeVXRTVaxart2.1331 of 5 stars$0.61-1.6%$3.00+393.6%-22.1%$110M$7.38M0.00109Analyst RevisionNews CoverageRANIRani Therapeutics3.1555 of 5 stars$2.05-0.5%$11.71+471.4%+2.5%$109.75M$2.72M0.00110Analyst ForecastDERMJourney Medical3.2915 of 5 stars$5.23-2.2%$9.38+79.3%N/A$108.42M$79.18M-5.6990Analyst RevisionPositive NewsIPSCCentury Therapeutics1.5719 of 5 stars$1.26-1.6%$11.60+820.6%-11.9%$107.14M$2.68M-0.68170 Related Companies and Tools Related Companies Elevation Oncology Competitors Celyad Oncology Competitors Precision BioSciences Competitors Atara Biotherapeutics Competitors Celularity Competitors Cabaletta Bio Competitors Vaxart Competitors Rani Therapeutics Competitors Journey Medical Competitors Century Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INKT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INKT Stock Alerts